Obesity Biotech Corxel Is Going Public in a Merger as Oral GLP-1 Heads to Phase 3
Corxel Pharmaceuticals is catching up to others with oral GLP-1 obesity drugs, but the biotech claims its small molecule could offer better tolerability compared to the rest of its class. The SPAC merger taking Corxel public is expected to close in the first half of 2027, which is when the biotech plans to start a Phase 3 trial.
Sutter Health Expands Remote Monitoring Program to Patients with Heart Failure
Sutter Health, a nonprofit healthcare system based in Sacramento, California, is expanding its digital chronic disease management program, Sutter Sync, to include patients with heart failure. The expansion adds a remote monitoring technology from San Francisco-based medical tech company Bodyport. The program expansion comes as health systems look for ways to identify deterioration in a low acuity environment before patients reach the point of needing emergency hospitalization.
In a Maternity Care Crisis, CMS Undermines Efforts To Modernize Care
CMS has introduced uncertainty about whether Medicare will participate in that modernization or preserve the old system under a different name. The consequences extend far beyond billing
FDA Alignment Is a Starting Point, Not a Rare Disease Strategy for the European Market
For US biotech companies developing rare disease therapies, decisions about clinical evidence, patient populations and regulatory advice can have consequences in Europe long before a marketing application is submitted.
CareValidate Launches Expanded HRT Offering
CareValidate expanded its HRT offering for telehealth companies, combining hormone therapy with provider access, pharmacy services and AI-powered care coordination.